NCT02028312

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Edward Holland, MD · Academic / Other
• Sex: All
• Age: 21 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel 0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in subjects with dry eye.

Conditions

• Dry Eye Disease

Interventions

Type	Name	Description
DRUG	Loteprednol etabonate
DRUG	Artificial Tears
DRUG	Restasis

Timeline

• Start date: 2014-01-01
• Primary completion: 2016-02-01
• Completion: 2016-06-01
• First posted: 2014-01-07
• Last updated: 2015-03-18

Locations

1 site across 1 country: United States